Malignant Mesothelioma Clinical Trial
Official title:
Mesothelioma and Radical Surgery Trial
Verified date | July 2009 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses
high-energy x-rays to kill tumor cells. Giving combination chemotherapy before surgery may
shrink the tumor so that it can be removed. Giving radiation therapy after surgery may kill
any tumor cells that remain after surgery. It is not yet known whether combination
chemotherapy is more effective with or without surgery and radiation therapy in treating
mesothelioma.
PURPOSE: This randomized clinical trial is studying combination chemotherapy, surgery, and
radiation therapy to see how well they work compared to combination chemotherapy alone in
treating patients with mesothelioma that can be removed by surgery.
Status | Active, not recruiting |
Enrollment | 670 |
Est. completion date | |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically and immuno-histochemically confirmed malignant mesothelioma - Resectable disease (T1-3, N0-1, M0) with no distant metastases - Eligible to undergo extra-pleural pneumonectomy based on British Thoracic Society guidelines PATIENT CHARACTERISTICS: Performance status - WHO 0-1 Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Normal renal function Cardiovascular - Ejection fraction = 40% Pulmonary - Predicted post-operative FEV_1 = 40% - Predicted post-operative DLCO = 40% - No significant pulmonary hypertension Other - No physical or personal condition that would preclude ability to undergo chemotherapy or post-operative radiotherapy - No physical or personal condition that would preclude ability to comply with follow-up requirements PRIOR CONCURRENT THERAPY: - Not specified |
Allocation: Randomized, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Birmingham Heartlands Hospital | Birmingham | England |
United Kingdom | Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust | Birmingham | England |
United Kingdom | Bristol Royal Infirmary | Bristol | England |
United Kingdom | Queen's Hospital | Burton-upon-Trent | England |
United Kingdom | Addenbrooke's Hospital | Cambridge | England |
United Kingdom | Papworth Hospital | Cambridge | England |
United Kingdom | Ipswich Hospital | Ipswich | England |
United Kingdom | Cookridge Hospital | Leeds | England |
United Kingdom | Glenfield Hospital | Leicester | England |
United Kingdom | Leicester Royal Infirmary | Leicester | England |
United Kingdom | Royal Marsden - London | London | England |
United Kingdom | St. Thomas' Hospital | London | England |
United Kingdom | Nottingham City Hospital NHS Trust | Nottingham | England |
United Kingdom | Berkshire Cancer Centre at Royal Berkshire Hospital | Reading | England |
United Kingdom | Cancer Research Centre at Weston Park Hospital | Sheffield | England |
United Kingdom | Institute of Cancer Research - Sutton | Sutton | England |
United Kingdom | Royal Marsden - Surrey | Sutton | England |
Lead Sponsor | Collaborator |
---|---|
Institute of Cancer Research, United Kingdom |
United Kingdom,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06057935 -
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
|
Phase 2 | |
Completed |
NCT00075699 -
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 3 | |
Completed |
NCT00821860 -
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
|
Phase 3 | |
Completed |
NCT00004033 -
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT03678350 -
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
|
Phase 1 | |
Recruiting |
NCT02580747 -
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|
Phase 1 | |
Completed |
NCT00398138 -
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
|
Phase 1 | |
Completed |
NCT00019825 -
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
|
Phase 1 | |
Terminated |
NCT00898547 -
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
|
||
Active, not recruiting |
NCT00030459 -
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00004183 -
Capecitabine in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00004920 -
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
|
Phase 3 | |
Completed |
NCT00005636 -
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
|
Phase 3 | |
Completed |
NCT00004254 -
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
|
Phase 2 | |
Completed |
NCT00334594 -
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT01291420 -
Dendritic Cell Vaccination for Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
Active, not recruiting |
NCT01649024 -
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00513877 -
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00372840 -
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
|
N/A |